Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
NPS Pharmaceuticals
February 16, 2016
Zealand plays catch-up with Shire in short bowel syndrome
April 10, 2015
Shire shines as a post-AbbVie solo act
January 15, 2015
Mega-merger drought fails to impede record-breaking acquisition year
January 12, 2015
Natpara risk overshadows Shire’s NPS takeout
November 04, 2014
PD-1s make way for the next wave of blockbuster launches
October 16, 2014
Shabbvie is dead; long live Shire
October 10, 2014
Upcoming events: Rett data for Neuren while NPS awaits Natpara approval
September 22, 2014
Still unpartnered, but now worth a lot more
August 29, 2014
Upcoming events: FDA panels take on liraglutide and Natpara
July 22, 2014
Small-molecule launches hold their own
February 19, 2014
Vantage Point – Four-tier drug plans thrust affordability into spotlight
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
October 20, 2020
Finding the next Vertex
October 15, 2020
Clinical setback lays bare Vertex’s weakness
October 15, 2020
SITC 2020 – embargo snafu triggers the first movers
October 19, 2020
Biopharma buyouts still pricey
September 30, 2020
More biotechs test the third way to market
